Recarbrio (imipenem/cilastatin/relebactam) launched in UK

Recarbrio, which contains relebactam, a non-beta lactam inhibitor of Ambler class A and class C beta-lactamases, is licensed for the treatment of infections caused by aerobic Gram-negative organisms in adults with limited treatment options.

PharmaTimes